Werewolf Therapeutics, Inc. (HOWL) Tops Q2 EPS by 36c
Get Alerts HOWL Hot Sheet
Join SI Premium – FREE
Werewolf Therapeutics, Inc. (NASDAQ: HOWL) reported Q2 EPS of $0.08, $0.36 better than the analyst estimate of ($0.28). Revenue for the quarter came in at $21 million.
For earnings history and earnings-related data on Werewolf Therapeutics, Inc. (HOWL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- StoneX Starts SoFi Technologies (SOFI) at Buy
- Elon Musk spends $366 million on 2026 US midterm elections
- Biomea Fusion to release Phase I data for oral GLP-1 drug BMF-650
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share